Mammary Fibroadenoma
Learn what the condition is, how it may be detected early, how it is treated or managed, and which breeds or species are linked to it.
Condition snapshot
A concise guide to the condition’s pattern, detection, management and urgency.
This snapshot is a general guide, not a diagnosis or treatment plan. New, severe or worsening signs require veterinary assessment.
About the condition
Fibroadenomas are hormone-responsive benign mammary tumours common in rats and also seen in mice. Although non-metastatic, they may become very large because mammary tissue extends over much of the body.
A soft or firm mobile mass may enlarge rapidly, interfere with movement, ulcerate or become traumatised. Multiple masses can develop over time.
Fibroadenomas are common benign, hormone-responsive mammary tumours in rats and mice. Mammary tissue extends from the neck and axilla to the groin, allowing a mass to appear almost anywhere under the skin. Although they do not usually metastasise, fibroadenomas may grow rapidly, become heavier than the animal can carry, ulcerate from floor contact or interfere with breathing and grooming. A soft mobile feel suggests but does not prove the diagnosis; carcinoma, abscess and other soft-tissue tumours can appear similar. Multiple or sequential masses are common because the remaining mammary tissue retains the same predisposition. Delaying surgery until skin is stretched and the rat is debilitated makes closure and recovery harder. Hormonal and reproductive status influence development, but individual strain and age are also important.
Fibroadenomas are benign hormone-responsive mammary tumours common in rats and mice. Their lack of metastasis does not make them harmless: rapid enlargement stretches skin, interferes with movement and can outgrow its blood supply. Mammary tissue extends widely, so a mass can arise near neck, shoulder or groin. Mobile softness is suggestive but does not exclude carcinoma or another soft-tissue tumour. New masses commonly arise elsewhere because remaining tissue retains the same predisposition. Floor contact abrades the dependent surface as the mass enlarges, and loss of mobility can produce pressure injury elsewhere. Tumour weight also masks continuing decline in lean body condition during serial weight checks.
Screening & Early Detection
Perform weekly body checks and seek assessment before a mass impairs movement or skin integrity.
Examination and cytology help assessment, but histopathology after excision confirms the diagnosis and excludes malignancy. Examine the entire mammary distribution and measure each mass in three dimensions at least weekly while awaiting treatment. Assess attachment to skin or deeper tissue, ulceration and regional lymph nodes. Cytology can support a mammary origin, but histopathology after excision confirms fibroadenoma and excludes malignancy. Chest imaging and blood testing are selected for older or systemically unwell animals. Record growth rate, body weight apart from the mass, previous tumours and ability to move and groom.
Bleeding, ulceration or sudden inability to walk requires prompt treatment. Measure the mass weekly while surgery is planned and assess attachment, ulceration, body weight apart from the tumour and ability to groom. Examine the complete mammary chain for additional lesions. Histopathology after excision confirms the benign classification rather than relying on gross appearance. Photograph the dependent skin surface and record mobility, since ulcer risk and functional burden can rise faster than the measured diameter.
Treatment & Management
Early surgical removal is preferred while the mass is small. Hormonal management and desexing may reduce recurrence in selected rats, but anaesthetic risk and age must be considered.
Surgical excision while the mass is small is the preferred treatment and usually permits easier haemostasis and closure. Submit tissue for histopathology even when it appears classically benign. Provide analgesia, warmth and nutritional support and protect the incision from chewing. Desexing or hormonal approaches may reduce future stimulation in selected rats, but evidence, age and anaesthetic burden must be considered individually. Continue weekly checks because a new fibroadenoma can arise at another site after successful surgery. When repeated masses or severe concurrent disease make further anaesthesia unreasonable, palliative wound protection and an explicit mobility and quality-of-life plan are needed.
Excise while the mass is small enough for straightforward haemostasis and closure. Provide analgesia, warmth and incision protection and restore mobility gradually. Desexing or hormonal management may influence recurrence in selected animals but is weighed against age and anaesthetic burden. Continue regular checks for new independent masses. After surgery, distinguish a local recurrence from a new tumour arising elsewhere and reconsider anaesthetic burden before repeated procedures.
Breeds or species affected
Standard Fancy Rat
Open small mammal description, care requirements and conditions
Dumbo Rat
Open small mammal description, care requirements and conditions
Rex Rat
Open small mammal description, care requirements and conditions
Hairless Rat
Open small mammal description, care requirements and conditions
Standard Fancy Mouse
Open small mammal description, care requirements and conditions
Satin Mouse
Open small mammal description, care requirements and conditions
Longhaired Mouse
Open small mammal description, care requirements and conditions